StockGlow

Genfit S.A. (GNFT.PA)

Develops medicines and diagnostic tests for liver and metabolic diseases.

13.20-0.03%Healthcare
Compare GNFT.PA with
StockGlow Score
92
Bullish
BearishBullish
1 year ago+291.9%

The outlook

GNFT.PA is trading at 13.2, well above both its 50- and 200-day moving averages and near the top of its 52-week range. Analyst consensus sits roughly 20% above the current price. The overall sentiment leans bullish based on current technical positioning and target levels.

What’s behind the score

Price trendAbove its 50- & 200-day averages
52-week range90% of the way from its 52-week low to high
Price targetAvg target +20% vs current price

Analyst price target

~12-month · 4 analysts
15.90average target+20.5% vs now
Now 13.20
Low 15.00High 18.60

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$661.3M
52-wk high
14.32
52-wk low
3.05
50-day avg
10.74
200-day avg
7.52
Trailing P/E
—

Similar stocks

IPH.PAInnate Pharma S.A.$1.60-1.23%NANO.PANanobiotix S.A.$32.84-6.81%DBV.PADBV Technologies S.A.$2.37-2.79%ALCLS.PACellectis S.A.$2.51-1.41%ADOC.PAAdocia SA$3.96+1.54%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy